Synthekine is a pioneering brand that applies distinct protein engineering platforms to develop immunotherapies. Their goal is to unlock the full efficacy potential of cytokines, which are essential for immune cell communication, while avoiding the toxicities associated with their pleiotropy. With a world-class team of experts in cytokine biology, immunology, and drug development, Synthekine is on a mission to become a leader in developing selective immunotherapies.

Cytokines play a crucial role in the body's response to diseases like cancer and in maintaining immune homeostasis. However, their pleiotropy, or ability to exert multiple responses on different cell types, has limited their therapeutic potential. Synthekine's innovative approach aims to overcome these limitations by leveraging the expertise of their founder, Dr.

K. Christopher Garcia, and their team's decades of discovery and drug development experience. Led by an experienced management team, Synthekine is dedicated to building a leading immunotherapy company.

Their pipeline consists of specific, selective, and potent cytokine therapeutics targeting a wide range of high-value targets. With a focus on harnessing the potential of cytokine therapeutics, Synthekine is committed to developing effective and safe treatments for patients in need